News

  • Aspira Women’s Health Announces Preliminary Second Quarter 2024 OvaSuite Product Volume and Highlights

    Preliminary OvaWatch® volume during Q2 2024 grew 24% over the prior quarter to 1,307 units Preliminary OvaSuiteSM volume during Q2 2024 grew 11% over the prior quarter to 6,471 units  AUSTIN, Texas, July 10, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused…

  • Aspira Women’s Health Announces Closing of $1.9 Million Private Placement Equity Financing

     July 09, 2024 12:12 ET  AUSTIN, Texas, July 09, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has closed its previously announced private placement for the issuance and sale of…

  • Aspira Women’s Health Announces $1.935 Million Private Placement Equity Financing

     July 01, 2024 17:24 ET  AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing…

  • Aspira Women’s Health Provides Commercial, Reimbursement and Cash Guidance Updates

     June 13, 2024 08:00 ET  Monthly OvaSuiteSM product volume grew by more than 26% in May compared to January Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite Cash used in operations guidance for 2024 expected to be lowered AUSTIN, Texas, June 13, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the…

  • Aspira Women’s Health to Present at the A.G.P. Healthcare Showcase on May 21

     May 16, 2024 08:00 ET  AUSTIN, Texas, May 16, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the Alliance Global Partner’s Healthcare Showcase taking…

  • Aspira Women’s Health Reports First Quarter 2024 Financial Results

     May 15, 2024 07:30 ET  Q1 2024 OvaSuiteSM revenue of $2.2 million and volume of 5,829 units Q1 2024 cash utilization of $4.4 million, a decrease of 22% compared to Q1 2023 Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc.…

  • Aspira Women’s Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15

     May 08, 2024 08:47 ET  AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31,…

  • Aspira Women’s Health Announces Publication of Two OvaWatch Peer-Reviewed Manuscripts

     May 07, 2024 08:00 ET  AUSTIN, Texas, May 07, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of two peer-reviewed manuscripts. The first manuscript, entitled “Ovarian Cancer Surgical Consideration is…

  • Aspira Women’s Health Enhances its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of OvaWatch

     May 02, 2024 08:00 ET  AUSTIN, Texas, May 02, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the formal launch of an updated OvaWatch ovarian cancer risk assessment test following the completion…

  • Aspira Women’s Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California

    Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid  April 09, 2024 08:00 ET  AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a new agreement…

  • Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results

     March 28, 2024 07:30 ET  2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter and full-year 2023 to $3.5 million and $15.9 million, respectively Conference Call and Webcast scheduled for today at 8:30 am…

  • Aspira Women’s Health Announces New Time for its Fourth Quarter and 2023 Year End Earnings Results and Call

    Management to Announce Earnings Results on Thursday, March 28, and hold a call at 8:30 am ET  March 25, 2024 08:00 ET  AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools,…

  • Aspira Women’s Health to Present at the MedInvest Biotech & Pharma Investor Conference

     March 21, 2024 08:00 ET  AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference…

  • Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President

     March 18, 2024 08:00 ET  Dr. Milligan brings a wealth of experience across critical business functions and deep relationships with leaders throughout the healthcare and pharmaceutical sectors Aspira also announces Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team following the departure of Dr. Jody Berry AUSTIN, Texas,…

  • Aspira Women’s Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024

     March 11, 2024 08:00 ET  AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended…

  • Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference

     February 22, 2024 08:30 ET  AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana’s 3rd…

  • Aspira Women’s Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)

     February 12, 2024 08:00 ET  AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a late-breaking poster presentation at the upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)…

  • Aspira Women’s Health Announces OvaSuite(SM) Distribution Agreement in the Philippines

     February 06, 2024 08:00 ET  Hi-Precision Laboratories, one of the largest medical laboratories in the Philippines, signs a 5-year OvaSuitSM commercial distribution agreement AUSTIN, Texas, Feb. 06, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools,…

  • Aspira Women’s Health Announces $5.5 Million Registered Direct Offering and Concurrent Private Placement

     January 25, 2024 08:00 ET  AUSTIN, Texas, Jan. 25, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has entered into definitive agreements with a single healthcare focused institutional investor alongside…

  • Aspira Women’s Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024

     December 19, 2023 08:00 ET  AUSTIN, Texas, Dec. 19, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it will host a virtual R&D day featuring experts who will present the exciting…

  • Aspira Women’s Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024

     December 14, 2023 08:00 ET  Aspira management will be available for meetings in San Francisco (January 8-10, 2024) AUSTIN, Texas, Dec. 14, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will be available for…

  • Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis

     December 06, 2023 08:00 ET  Data supports EndoCheck™ to be the first blood test for the identification of localized endometriosis, including endometrioma Platform migration to begin on the Company’s EndoMDx™ test for broader endometriosis indications AUSTIN, Texas, Dec. 06, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused…

  • Aspira Women’s Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)

    California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test  November 28, 2023 08:00 ET  AUSTIN, Texas, Nov. 28, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that California Medicaid (Medi-Cal) added…

  • Aspira Women’s Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

     November 27, 2023 09:47 ET  CMS approves OvaWatchSM 2024 price at $897 per test AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS)…

  • Aspira Women’s Health Reports Third Quarter 2023 Financial Results

     November 13, 2023 16:05 ET  Product revenue increased 9% to $2.2 million for the quarter, and 19% to $7.0 million year to date OvaSuite sales volume increased 5% to 5,783 units for the quarter, and 16% to 18,331 units year to date Third quarter cash utilization of $3.3 million, a decrease of 56% compared to…